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Abstract 
Background: Despite recent improvements in survival due to advances in treatment, the quality of life of patients 
with lymphoma may be compromised by the long-term complications of chemotherapy and steroid therapy. Among 
these, a potentially relevant problem is bone loss and the development of fragility fractures.
Aim: To provide further evidence of clinical or subclinical skeletal complications in correlation with biological vari-
ables and markers of bone disease in patients with complete response to therapy.
Method: A cross-sectional observational study was conducted on subjects diagnosed with lymphoma with subse-
quent antineoplastic treatment, disease status after therapy defined as complete response disease for at least a year 
now. We performed: blood chemistry tests, imaging techniques and screening tools for the assessment of functional 
status and quality of life (SARC-F and mini-Osteoporosis Quality of Life).
Results: Approximately 50% of patients had osteoporosis, with a prevalence of vertebral fractures of 65.5%. In most 
patients, we found hypovitaminosis D and high levels of parathyroid hormone (PTH). Furthermore, a statistically 
significant association was observed between high PTH levels and previous lymphoma treatment. Finally, the Mini-
Osteoporosis Quality of life (mini-OQLQ) questionnaire demonstrated a loss of quality of life as a consequence of the 
change in bone status.
Conclusions: Patient treatment design for personalized chemotherapy would be desirable to reduce late effects on 
bone. Also, early prevention programs need to be applied before starting treatment. The most benefited subpopula-
tions could be not only elderly but also young patients.
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Introduction
Despite recent improvements in survival because of 
advances in treatment, quality of life of patients with lym-
phoma may be compromised by long-term complications 
of chemo and steroid therapy [1]. A potentially relevant 
issue for lymphoma survivors is bone loss - osteope-
nia and osteoporosis- as consequence of the treatment. 
Osteoporosis can lead to development of fragility frac-
tures, a major cause of morbidity associated with consid-
erable mortality [2].
Some studies have evaluated the occurrence and the 
impact of bone loss in adult patients with hematologi-
cal neoplasms including lymphomas [3]. Baseline test-
ing of bone mineral density (BMD) reveals osteopenia 
or osteoporosis in the majority of Non Hodgkin lym-
phoma (NHL) patient s[4].Patients with lymphoma have 
significant bone loss compared to the normal general 
populatio n[5], because it is known that the therapy of 
lymphoma with high-dose glucocorticoids and alkylating 
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agents may result in premature bone loss, increasing the 
risk of vertebral and hip fractures. It is also observed that 
low BMD seen at diagnosis may worsen after lymphoma 
therapy [6, 7].
Glucocorticoids increase bone resorption and reduce 
bone formation by inhibiting the formation of osteoblast 
precursors and inducing apoptosis of mature osteocytes. 
They also determine a reduction in intestinal absorp-
tion of calcium and muscle mass. Alkylating agents, in 
addition to their important cardiotoxic effect [8], also 
negatively influence bone metabolism through their gen-
otoxic action which determines early menopause in these 
patients, especially of female sex [9].
The effects on the bone of individual drugs and com-
bined therapeutic regimes are complex, and the lack of 
clear knowledge about molecular pathways and regula-
tory events does not make it easy to implement effective 
prevention strategies in patients with lymphoma [10].
To date, very few studies have described functional sta-
tus of bone with comprehensive analysis of clinical fea-
tures, biochemical parameters and imaging studies in 
previously treated patients for lymphoma.
Unlike hormone-sensitive tumors undergoing hor-
mone replacement therapy, such as breast cancer and 
prostate cancer, where there is now unanimous agree-
ment on the role and effectiveness of primary preventive 
therapy on bone health, in the case of lymphomas, most 
patients treated with chemotherapy do not receive prior 
treatment of osteoporosis, although some studies have 
shown a clear loss of bone mass in these patients, espe-
cially in the first two years after treatmen t[9–11].
A critical role in bone mineral metabolism is played 
by PTH and vitamin D. They form a tightly controlled 
feedback loop, as PTH is one of the main stimulators 
of vitamin D synthesis in the kidney, while vitamin D 
exerts negative feedback on the PTH secretion. PTH is 
the main physiological regulator of serum calcium con-
centration. Through its effects on the intestines, kidneys, 
and bones it keeps serum calcium within a narrow range. 
Conversely, vitamin D has a stimulating effect on both 
calcium and phosphate homeostasis, playing a key role in 
providing adequate mineral for normal bone formation 
[12].High levels of PTH and/or low levels of Vitamin D 
can promote the onset of osteoporosis. In patients with 
lymphoma, a condition of Vitamin D deficiency/insuf-
ficiency is often identified, correlating with a worse out-
come of the disease. Furthermore, vitamin D also appears 
to play an important role in malignant hematological 
cells. In the latter, supplementing with vitamin D pro-
motes apoptosis and inhibits its proliferation. Although 
the dosage of vitamin D required to achieve these effects 
may induce hypercalcemia in humans, analogs have been 
developed that can avoid this side effect [13, 14].
This real-world study was conducted to provide further 
evidence of clinical or subclinical skeletal complications, 
possibly correlating with major bone disease markers 
(such as Vitamin D and PTH), and ultimately to assess 
the quality of life in relation to sarcopenia in patients 
with complete response lymphoma to treatment.
Patients and methods
Study design and population
This is an observational, cross-sectional study conducted 
at Policlinico “PaoloGiaccone” of Palermo. within an 
interdisciplinary setting involving Hematology Unit 
and Physiatric Unit. The patients were recruited from 
March 2018 to July 2020. The study was conducted in 
accordance with the Declaration of Helsinki and with 
the approval from the Ethical Committee, n. 02/2018. All 
participants provided written informed consent before 
study entry.
Inclusion criteria comprised: age between 16 and 
85  years, previous diagnosis of lymphoma with sub-
sequent antineoplastic treatment, disease status after 
therapy defined as complete response for at least a year 
[9]. Exclusion criteria were as follows: patients with 
progressive disease following first-line chemotherapy; 
patients treated with more than 1 line of chemother-
apy; any previous o current treatment for osteoporosis; 
other concomitant malignancies both with and without 
metastasis; concurrent systemic inflammatory rheumatic 
disease; history of metabolic bone disease; renal insuffi-
ciency stage 4 and 5; any medical comorbidity that may 
cause osteoporosis and/or other variables alterations; 
physical disabilities that may prevent the patient to fully 
understand and adhere to study procedures; patients 
with previous known vertebral fractures for non-osteo-
porotic reasons; patients not able to understand and give 
informed consent.
Assessments
Baseline data regarding demographic and clinical infor-
mation was collected from clinical charts. Variables col-
lected from this source were: age, gender, body mass 
index (BMI), type of lymphoma, histotype of lymphoma, 
treatment protocol received, and comorbidities. At the 
time of the physiatric consultation, other variables were 
evaluated for the evaluation of bone metabolism, such as 
blood levels of Vitamin D and PTH. Furthermore, BMD, 
T-score and Z-score of the femoral and lumbar spine 
were also evaluated using the densitometric examina-
tion, and through thoracolumbar radiographic scans with 
morphometric count according to the Genant criteria, 
the presence of vertebral fragility fractures was assessed.
The following evaluation questionnaires were also 
administered to all patients: SARC-F questionnaire, for 
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the screening of sarcopenia; and Mini-OQLQ to assess 
the quality of life in relation to osteoporosis.
For the measurement of vitamin D levels, we used 
the following reference cut-off:20  ng/ml deficiency, 
20–30  ng/ml insufficiency, and normal 30–100  ng/m 
l[15].The reference cut-offs used for the measurement of 
parathormone levels were:70  pg/Ml normal values and 
70 pg/ml high values (hyperparathyroidism )[16].
Dual-energy x-ray absorptiometry (DEXA) scans of 
the femoral neck and lumbar spine were performed to 
detected BMD. According to the World Health Organi-
zation criteria, osteopenia is defined as a T score 
between − 1 > − 2.5, and osteoporosis is defined as a T 
score > − 2.5 or les s[17].
Genant morphometric counting (or semi-quantitative 
criteria) is a radiological method used to identify the 
presence of vertebral fractures and applies to vertebrae 
T4 to L4. According to these criteria, a normal vertebra 
is defined as grade 0. A grade 1 deformity is defined by a 
reduction of 20–25% of the anterior, middle, and/or pos-
terior vertebral height and 10–20% of the area. A grade 
2 deformity is defined by a reduction of 26–40% in any 
height and 20–40% in the area. Finally, a grade 3 deform-
ity is defined by a reduction of > 40% of any height and 
are a[18].
The SARC-F questionnaire (five-voice questionnaire) is 
a screening tool for sarcopeni a[19, 20].SARC-F includes 
five components: strength, assistance walking, rise from 
a chair, climb stairs, and falls. Scale scores range from 
0 to 10 (i.e. 0–2 points for each component; 0 = best to 
10 = worst).
The mini-OQL Q[21]includes two items in each of five 
domains (symptoms, physical function, activities of daily 
living, emotional function, leisure activities). For each 
of the 10 questions a mark between 1 and 7 is assigned: 
score 1 corresponds to the worst possible function 
(extreme difficulty, permanent fear and extreme anxiety), 
instead score 7 is associated with the better function pos-
sible (absence of difficulty, of fear and anxiety). The total 
score of the questionnaire can vary from minimum of 10 
to maximum of 70. The data collected were analyzed by 
calculating mean, median and mode values of total score. 
Finally, a possible correlation has been evaluated between 
osteoporosis secondary to lymphoma and some of the 
main markers of bone metabolism such as PTH and 
Vitamin D, also in consideration of other demographic 
variables (age, sex) and clinical (type of treatment, 
comorbidity, sarcopenia, and quality of life).
Statistical analysis
All the information collected from patients enrolled were 
entered into an electronic database created by Excel 16.0 
software.
All quantitative values were expressed as mean ± SD or 
median with interquartiles. The Kolmogorov–Smirnov 
test was used to verify thenormality of the distribution 
of the study variables. Absolute and relative frequen-
cies were obtainedto the data collected: age, sex, BMI, 
Vit D, PTH, femoral BMD and vertebral BMD, type of 
lymphoma, comorbility, number of vertebral fractures, 
DEXA femoral, SARC-F and Mini-OQoL.
The sample was stratified and analysed trough a uni-
variate analysis by Vitamin D and Parathormone levels.
The differences in the categorical variables for levels 
of Vitamin D and Parathormone were analysed using 
Mann-Whitney test for the quantitative variables and 
Fisher exact test for categorical variables. Since the sam-
ple size is low, we use a non-parametrical test on the 
medians and an exact test to evaluate the associations. 
We also used the Pearson correlation coefficient to evalu-
ate the linear correlation among some quantitative vari-
ables. The level of significance chosen for the univariate 
analysis was 0.05 (two tailed). All the data were analysed 
using the statistical software R (R Core Team, 2021).
Results
A total of 29 patients previously treated with lymphotox-
ictherapy (chemotherapy, radiotherapy, steroid) for lym-
phoma were evaluated. Overall demographic and clinical 
features are shown in Table 1.
The patient group included 18 males (62.1%) and 
11 females (37.9%). The mean age of the entire study 
group was 61.4  years (SD 16,7). The average BMI was 
27.1 ± 4.3.4 subjects (13.8%)had a diagnosis of Hodg-
kin Lymphoma (HL), and 25 (86.2%) of NHL. In the 25 
patients with NHL, the most common histology was: 
large B cell lymphoma (DLBCL) (48%), follicular lym-
phoma (FL) (24%), and marginal zone lymphoma (MZL) 
(16%).Overall, 12 patients (41.4%) reported 3 or more 
comorbidities and 10 patients (34.5%) one or two.All 
recruited patients received chemotherapy treatment, 
while only 4 (13.8%) also received radiotherapy and 17 
patients received corticosteroid therapy.
Table 2 shows the results of the variables analyzed for 
bone metabolism.The average vitamin D levels in the 
sample were 21.6 ng/ml (SD 8.8): in 5 patients they were 
normal (17.2%), while insufficient and deficient respec-
tively in 22 (75.9%) and 2 (6.9%) cases. PTH values were 
high in 6 patients (20.7%), in the normal range in 20 
cases (69%) and low in 3 cases (10.3%) with an average of 
43.5 pg/ml (SD 26.8).
Femural DEXA was determined in 27 patients, while 
the other 2 patients had bilateral hip prostheses, with 
these results of T-score: normal in 15 cases (55.6%), 
osteopenia in 10 (37%), osteoporosis in 2 (7.4%). The 
calculated average T-score was − 0.8 (DS 1.2) and the 
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average Z-score − 0.1 (DS 1.1). Vertebral lumbar DEXA 
was performed in 28 patients, because one hadhad verte-
bral stabilization:14 of them (50%) had normal findings, 7 
(25%) had osteopenia and 7 (25%) osteoporosis. The aver-
age calculated T-score was − 1 8 (DS 1.5) and the average 
Z-score was − 0.2 (DS 1.4).
As for vertebral fractures, 10 (34.5%) patients had no 
fractures, but 10 (34.5%) had 1 or 2 fractures and 9 (31%) 
had 3 or more than one fracture. The average value was 
2.1 (DS 1.8).
The average SARC-F values were 3.8 (DS 1.9). In Fig. 1 
shows the distribution of patients with a SARC-F of less 
than 4 points (38%) compared to those with a score of 4 
or more (62%).
MINI-OQoL detected a mean total score of 54.4 ± 11.1 
and a median total score of 55 (range 32–70). In Fig. 2, 
patients were classified by scores obtained at the ques-
tionnaire: the 37.9% of the patients was classified with a 
mild OQoL score (> 60 points), the 55.2% had a moderate 
score (36–60 points), while the 6.9% had a severe score 
(< 36 points). So the observed mode is the moderate 
score (36–60 points).
Table 3 shows the results of the correlation between the 
blood values of Vitamin D and PTH and the demographic 
and clinical characteristics of the patients.
We show that older patients carry significantly higher 
levels of PTH (p = 0.02). In patients undergoing com-
bined treatment with multiple chemotherapeutic agents 
and high doses of corticosteroids, a significant asso-
ciation with high levels of PTH (p = 0.02) was observed. 
Furthermore, a significant association was found between 
higher PTH levels and vertebral fractures (p = 0.05).
Table 3 also shows that SARC-F values greater than or 
equal to 4 points are almost significantly associated with 
Vitamin D deficiency/deficiency values (p = 0.06) with 
a Pearson correlation coefficient equal to − 0.29 indica-
tive of a moderate negative linear correlation between 
the two variables. Finally, through Pearson’s correlation, 
a weak positive linear correlation was also highlighted 
between the Mini-OQoL score and the Vitamin D values, 
with a Pearson index of 0.13.
Discussion
Our study exploring bone damage after lymphoma 
treatment adds information on the late effects of cancer 
therapy in survivors of adult patients. In this interdis-
ciplinary study, we identified subjects with lymphoma 
in complete remission for at least one year, who under-
went a screening program for osteoporosis to evaluate 
Table 1 Blood chemistry values, BMD findings by DEXA, 
verterbral fractures, sarcopenia assessment
N° (%) Mean (SD)
Sex Male 19 (65.5)
Female 10 (34.5)
Age 61.4 ± 16.7
BMI 27.1 ± 4.3









LGL leukemia 1 (4.0)
Comorbidities ≥ 3 12 (41.4)
1 or 2 10 (34.5)
No 7 (24.1)
Chemotherapy Yes 29 (100.0)
No 0 (0.0)
Radiotherapy Yes 4 (13.8)
No 25 (86.2)
Corticosteroid Therapy Yes 17 (58.6)
No 12 (41.4)
Table 2 Variables for the evaluation of bone metabolism
No. (%) Mean ± SD
Vitamin D (ng/ml) Normal (31–100) 5 (17,2) 21.6 ± 8.8
Insufficiency (11–30) 22 (75,9)
Deficiency (≤10) 2 (6,9)
PTH (pg/ml) High (> 70) 6 (20,7) 43.5 ± 26.8
Normal (12–70) 20 (69,0)
Low (< 12) 3 (10,3)
BMD Femural (g/cm2) 0.9 ± 0.1
T-Score Femural Normal 15 (55,6) −0.8 ± 1.2
Osteopenia 10 (37,0)
Osteoporosis 2 (7,4)
Z-Score Femural −0.1 ± 1.1
BMD Lumbar Vertebral 0.9 ± 0.2
T-Score Lumbar Vertebral Normal 14 (50,0) −1.0 ± 1.5
Osteopenia 7 (25,0)
Osteoporosis 7 (25,0)
Z-Score Lumbar Vertebral −0.2 ± 1.4
Vertebral Fractures No 10 (34,5) 2.1 ± 1.8
1 or 2 10 (34,5)
≥3 9 (31,0)
SARC-F ≥4 (sarcopenic) 18 (62) 3.8 ± 1.9
< 4 (non sarcopenic) 11 (38)
Mini OQoL Mild 11 (37,9)
Moderate 16 (55,2) 54.4 ± 11.1
Severe 2 (6,9)
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the relationship with predictive markers, the presence 
of vertebral fractures of unknown fragility, and the 
effects on muscle mass and the quality of life.
Previous studies conducted on this issue generally 
focused on patients prior to receive front-line therapy 
or on pediatric survivors, the latter examined, however, 
before peak bone mass achievement [22].
In the population under examination, we found hypo-
vitaminosis D in 82.8% of patients and high levels of 
PTH in 20.7%, conditions known to be associated with 
an increased risk of osteoporosis [23]..
Vitamin D deficiency is a known problem in many 
parts of the world, in fact, 1 in 7 people (14%) are thought 
to have vitamin D insufficiency or deficiency [24]. The 
role of vitamin D has been extensively studied in cancer 
patients however the conclusions are sometimes conflict-
ing [25, 26]. Some authors state that low serum levels of 
vitamin D are associated with a higher risk of develop-
ing NHL, which is also confirmed by other studies that 
conclude that sun exposure favors higher serum levels 
of vitamin D reducing the risk of developing NHL [25]. 
Furthermore, it is now known that vitamin D deficiency 
Fig. 1 Percentage of patients with SARC-F values > 4 and ≤ 4
Fig. 2 Mini QoL score
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represents a negative prognostic factor for patients with 
lymphoma, treated with chemotherapy in particular 
Rituximab plus cyclophosphamide, doxorubicin, vin-
cristine and prednisone (R-CHOP) [26], in fact, vitamin 
D supplementation can be useful to improve survival in 
these patients. The reduced blood concentration of Vit D 
in cancer patients can be a consequence not only of the 
antineoplastic treatment but also secondary to a condi-
tion of inactivity, isolation, and loss of appetite. In the 
aforementioned patients, a picture of sarcopenia is often 
established. In patients with lymphomas, we found that 
insufficient Vitamin D values were related to sarcopenia. 
More than half of the patients had a SARC-F question-
naire score at risk for sarcopenia. Sarcopenia combined 
with osteopenia/osteoporosis increases the chances of 
fracture [27–29].. The complex relationship between sar-
copenia and chemotherapy has been studied in the liter-
ature, as they create a vicious circle for musculoskeletal 
complications [30], assuming that antineoplastic drugs 
can affect muscle cells and worsen their function. It is 
now known that chemotherapeutics cause a reduction 
in muscle mass much faster than that related to normal 
aging. This is achieved through their myotoxic effects, 
as they cause mitochondrial dysfunction and oxidative 
stress, promoting skeletal muscle atrophy. All this is 
responsible for the high prevalence of asthenia, muscle 
weakness, and physical disability of cancer patients. This 
situation contributes to increasing inactivity and reduc-
ing the ability to stay outdoors and expose oneself to 
sunlight, the main source of Vit D production. Chemo-
therapy-induced sarcopenia is considered to be an unfa-
vorable prognostic factor for survival [30–32]..
This finding suggests that vitamin D dosage may help to 
identify patients not only at risk of developing fractures 
but also already suffering from musculoskeletal meta-
bolic alterations that may worsen the quoad valetudinem 
prognosis of patients with lymphoma. To date, this is the 
first approach to assess osteoporosis-related health status 
in lymphoma patients [33–35].
In addition to the above, in our study, we found that 
worse mini-OQoL scores are related to low vitamin D 
levels, with a moderate/severe impact on more than 
half of the population examined. The above supports 
the observation in real life that supplementation with 
vitamin D improves the ability to perform activities 
of daily life. The positive effects of vitamin D on qual-
ity of life have been widely reported in the literature. 
It can be considered an antioxidant agent as it can 
Table 3 Association of Vitamin D and Parathormone values with socio-demographic and clinical characteristics of the patients




Diagnosis Hodgkin lymphoma 1 (25.0) 2 (75.0) 0.46 0 (0.0) 3 (100.0) 0.56
Non-Hodgkin lymphoma 4 (16.0) 21 (84.0) 6 (23.1) 20 (76.9)
Age 63.0 (21.0) 66.0 (26.5) 0.49 62.0 (23.5) 77.0 (4.5) 0.02
Gender Male 5 (26.3) 14 (73.7) 0.14 5 (26.3) 14 (73.7) 0.63
Female 0 (0.0) 9 (100.0) 1 (10.) 9 (90.0)
Chemo and steroid therapy Yes 2 (12.5) 14 (87.5) 0.63 6 (37.5) 10 (62.5) 0.02
No 3 (23.1) 10 (76.9) 0 (0) 13 (100)
Comorbidities Yes 4 (18.2) 18 (81.8) 0.99 6 (27.3) 16 (72.7) 0.15
No 1 (14.3) 6 (85.7) 0 (0) 7 (100)
Vertebral fractures Yes 2 (10.5) 17 (89.5) 0.29 6 (31.6) 13 (68.4) 0.05
No 3 (33.3) 6 (66.7) 0 (0.0) 10 (100)
Femoral DEXA Normal 3 (20.0) 12 (80.0) 0.83 3 (20.0) 12 (80.0) 0.99
Osteopenia / Osteoporosis 1 (9.1) 10 (90.9) 3 (25.0) 9 (75.0)
Vertebral DEXA Normal 2 (14.3) 12 (85.7) 0.57 3 (21.4) 11 (78.6) 0.93
Osteopenia / Osteoporosis 3 (23.1) 10 (76.9) 3 (21.4) 11 (78.6)
Vitamin D (ng/ml) Normal / / / 0 (0.0) 5 (100.0) 0.30
Insuffiency / Deficiency 6 (26.1) 17 (73.9)
SARC-F (patients with 1 or 2 points) ≥4 (sarcopenic) 1 (5.9) 16 (94.1) 0.06 3 (16.7) 15 (83.3) 0.65
< 4 (non sarcopenic) 4 (36.4) 7 (63.6) 3 (27.3) 8 (72.7)
Mini-OQoL total score 10–35 1 (50,0) 1 (50,0) 2 (100,0) 0 (0,0) 0.14
36–60 2 (12,5) 14 (87,5) 0.63 11 (68,7) 5 (31,3)
61–70 2 (20,0) 8 (80,0) 10 (90,9) 1 (9,1)
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reduce the oxidative damage of proteins by reducing 
harmful carbonyl proteins. Furthermore, supplementa-
tion of vitamin D seems to induce an improvement in 
mood, although this effect has not been shown in can-
cer patients. As a consequence of these actions, vitamin 
D determines an improvement in muscle function and 
quality of life [36, 37].
Consistent with what happens in the general elderly 
population, hyperparathyroidism is also a condition asso-
ciated with advanced age in subjects with lymphomas. 
Normally in the elderly population serum, PTH levels 
are often higher than those in the younger population. 
All this is associated with an increased risk of osteosar-
copenia in the elderly, with poor functional status and 
an increased prevalence of falls and therefore fractures 
[38–40].
In our study, we also noted how hyperparathyroidism 
is also associated with antineoplastic treatment com-
bined with chemotherapy and corticosteroids [41]. This 
is even more relevant given the statistically significant 
correlation between vertebral fractures and hyperpar-
athyroidism in the study population. This confirms the 
contribution of PTH in predicting bone damage in the 
population studied. However, these observations do not 
definitively establish the functional importance of high 
PTH levels in individuals with lymphoma, but knowledge 
about the healthy population could be translated into 
patients with lymphoma [42, 43].
Further evidence of the negative impact of antineo-
plastic treatment on bone was highlighted by the finding 
of osteopenia and osteoporosis on DEXA in about half 
of the patients, particularly considering the presence of 
many young adults in the study group. of greater impor-
tance was the finding, in 65.5% of cases, of vertebral fra-
gility fractures, given their implications on morbidity and 
mortality.
These results are consistent with previous studies, i.e. 
systemic exposure to steroids at high doses can increase 
osteoporosis and fracture risk [42, 43]. Corticosteroids, 
especially when used chronically, lead to severe adverse 
effects on the musculoskeletal system. At the bone level, 
they increase the risk of osteoporosis, as they lead to 
an increase in bone resorption and a reduction in bone 
formation, by inhibiting osteoblast differentiation and 
osteocyte apoptosis. At the muscular level, on the other 
hand, they are responsible for proximal myopathy and 
muscle atrophy. These combined effects increase the 
prevalence of falls resulting in an increased risk of bone 
fractures [42, 43].
In relation to the data obtained, it would be desirable 
to measure the blood levels of Vitamin D and PTH, the 
execution of a DEXA, and radiographic examination of 
the thoracolumbar spine between routine examinations 
in patients with lymphoma, in order to counteract the 
negative effects on the bone early.
Limitations of our study include the sample size and 
selection bias inherent to different lymphoma subtypes 
with different chemotherapy protocols. Together, these 
data suggest that simple clinical check in asymptomatic 
patients is not yet sufficiently sensitive to screen bone 
loss or fractures after chemotherapy, it is necessary to 
supplement with humoral assays and imaging techniques.
Thus, upcoming prospective studies with larger case 
numbers are needed to further validate the best approach 
for monitoring bone damage in lymphoma patients, 
before and after chemotherapy.
Conclusioni
Despite generally favourable outcome, lymphoma 
patients experience an assortment of late complications.
Only recently the term “lymphoma survivorship” was 
coined and researchers have begun to assess long-term 
side effects of antineoplastic therapy. In addition to car-
diac concerns, infertility and secondary cancers, the 
musculoskeletal effects have been recognized as one of 
the most common potential risks [44–46]. Prevention 
and treatment of the bone damage in lymphoma patients 
often plays a minor role in clinical practice.
According to the results of our study, performing 
screening tests for osteoporosis in patients suffering 
from lymphomas should be recommended and should be 
included in clinical practice among the routine tests to be 
performed. Subjects at risk of osteoporosis. Despite bone 
damage can vary considerably, depending onparticular 
chemotherapy regimen and age, our current investigation 
supports a rationale for the hypothesis that lymphoprolif-
erative diseases and chemotherapy are itemsthat have to 
be taken into consideration for fracture risk stratification.
The study results suggest designing personalized lym-
phoma therapy and building an accurate follow-up plan, 
including bone health surveillance in long-term survi-
vors, to identify adverse events or, at least, diagnosing 
them promptly. Furthermore, it is necessary to apply for 
prevention programs before starting treatment, even in 
young patients, being a potentially not considered, but 
potentially affected subpopulation.
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